MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, PASG had $8,730K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$8,730K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Sales or maturities of marketabl...
    • Impairment of long-lived assets
    • Non-refundable sublicense and tr...
    • Others
Negative Cash Flow Breakdown
    • Accrued expenses and other curre...
    • Right of use assets and operatin...

Cash Flow
2025-12-31
Net loss
-45,522
Depreciation and amortization
728
Sharebased compensation
3,001
Amortization of premium and discount on marketable securities, net
129
Impairment of long-lived assets
6,145
Other non-cash items
14
Prepaid expenses and other current assets, and other assets
-228
Prepaid research and development
-391
Non-refundable sublicense and transition services payments received
4,015
Right of use assets and operating lease liabilities
464
Accounts payable
1,880
Accrued expenses and other current liabilities
-2,054
Net cash provided by (used in) operating activities
-31,509
Sales or maturities of marketable securities
39,046
Sales of property and equipment and other assets
1,170
Net cash provided by (used in) investing activities
40,216
Proceeds from the issuance of common stock under employee stock purchase plan
23
Net cash provided by (used in) financing activities
23
Net increase (decrease) in cash and cash equivalents
8,730
Cash and cash equivalents at beginning of year
37,573
Cash and cash equivalents at end of year
46,303
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Sales or maturities ofmarketable securities$39,046K Sales of property andequipment and other assets$1,170K Proceeds from theissuance of common stock...$23K Net cash provided by(used in) investing...$40,216K Net cash provided by(used in) financing...$23K Net increase(decrease) in cash and cash...$8,730K Canceled cashflow$31,509K Impairment of long-livedassets$6,145K Non-refundable sublicense andtransition services...$4,015K Sharebased compensation$3,001K Accounts payable$1,880K Depreciation andamortization$728K Prepaid research anddevelopment-$391K Prepaid expenses andother current assets,...-$228K Amortization of premium anddiscount on marketable...$129K Other non-cash items$14K Net cash provided by(used in) operating...-$31,509K Canceled cashflow$16,531K Net loss-$45,522K Accrued expenses andother current...-$2,054K Right of use assets andoperating lease...$464K

Passage BIO, Inc. (PASG)

Passage BIO, Inc. (PASG)